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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to a 
combination of Lactobacillus acidophilus BCCM/LMG P-18806, 
Lactobacillus delbrueckii BCCM/LMG P-18805 and Streptococcus 
thermophilus BCCM/LMG P-18807 and reduction of gastro-intestinal 
discomfort (ID 2946, 2951, 2974), decreasing potentially pathogenic gastro-
intestinal microorganisms (ID 2946, 2951, 2974), improved lactose digestion 
(ID 2946, 2951, 2974), and reduction in numbers of circulating CD34
+
 cells 
(ID 2947, 2952, 2975) (further assessment) pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to provide a scientific opinion on health claims pursuant to Article 13 of Regulation (EC) No 
1924/2006 in the framework of further assessment related to a combination of Lactobacillus acidophilus 
BCCM/LMG P-18806, Lactobacillus delbrueckii BCCM/LMG P-18805 and Streptococcus thermophilus 
BCCM/LMG P-18807 and reduction of gastro-intestinal discomfort, decreasing potentially pathogenic gastro-
intestinal microorganisms, improved lactose digestion, and reduction in numbers of circulating CD34
+
 cells. The 
food constituent that is the subject of the health claim, a combination of L. acidophilus BCCM/LMG P-18806, 
L. delbrueckii BCCM/LMG P-18805 and S. thermophilus BCCM/LMG P-18807, is sufficiently characterised. 
The evidence provided did not establish that the proposed claimed effect, reduction in numbers of circulating 
CD34
+
 cells, is a beneficial physiological effect. The claimed effect, reduction of gastro-intestinal discomfort, is 
a beneficial physiological effect for the general population. The claimed effect, a decrease in potentially 
pathogenic gastro-intestinal microorganisms, might be a beneficial physiological effect for the general 
population. The claimed effect, improved lactose digestion, is a beneficial physiological effect for individuals 
with lactose maldigestion. No human intervention studies were provided from which conclusions could be drawn 
for the scientific substantiation of the above-mentioned claims. On the basis of the data provided, the Panel 
concludes that a cause and effect relationship has not been established between the consumption of a 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2012-00180, EFSA-Q-2012-00181, EFSA-Q-2012-
00184, EFSA-Q-2012-00185, EFSA-Q-2012-00202, EFSA-Q-2012-00203, adopted on 28 June 2012. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu  
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Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. 
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combination of L. acidophilus BCCM/LMG P-18806, L. delbrueckii BCCM/LMG P-18805 and S. thermophilus 
BCCM/LMG P-18807 and reduction of gastro-intestinal discomfort, decreasing potentially pathogenic 
gastro-intestinal microorganisms, and improved lactose digestion.  
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to provide a scientific opinion on a list of health claims pursuant to Article 
13 of Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States that a 
certain number of Article 13 health claims would be eligible for further assessment by EFSA in order 
to be able to take a final decision on whether or not to include these claims in the list of permitted 
health claims. This opinion addresses the scientific substantiation of health claims in relation to a 
combination of Lactobacillus acidophilus BCCM/LMG P-18806, Lactobacillus delbrueckii 
BCCM/LMG P-18805 and Streptococcus thermophilus BCCM/LMG P-18807 and reduction of 
gastro-intestinal discomfort, decreasing potentially pathogenic gastro-intestinal microorganisms, 
improved lactose digestion, and reduction in numbers of circulating CD34
+
 cells. The scientific 
substantiation is based on the information provided by the competent Authority of Italy for further 
assessment of this claim.  
The food constituent that is the subject of the health claims is a combination of L. acidophilus 
BCCM/LMG P-18806, L. delbrueckii BCCM/LMG P-18805 and S. thermophilus BCCM/LMG 
P-18807. The Panel considers that the combination of L. acidophilus BCCM/LMG P-18806, 
L. delbrueckii BCCM/LMG P-18805 and S. thermophilus BCCM/LMG P-18807 is sufficiently 
characterised.  
Reduction of gastro-intestinal discomfort 
The claimed effect, which is proposed for further assessment, relates to a reduction of gastro-intestinal 
discomfort. The proposed target population is the general population. Reduction of gastro-intestinal 
discomfort is a beneficial physiological effect. 
No human intervention studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of L. acidophilus BCCM/LMG P-18806, 
L. delbrueckii BCCM/LMG P-18805 and S. thermophilus BCCM/LMG P-18807 and reduction of 
gastro-intestinal discomfort. 
Decreasing potentially pathogenic gastro-intestinal microorganisms  
The claimed effect, which is proposed for further assessment, relates to a decrease in potentially 
pathogenic gastro-intestinal microorganisms. The proposed target population is the general population. 
Decreasing potentially pathogenic gastro-intestinal microorganisms might be a beneficial 
physiological effect. 
No human intervention studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of L. acidophilus BCCM/LMG P-18806, 
L. delbrueckii BCCM/LMG P-18805 and S. thermophilus BCCM/LMG P-18807 and decreasing 
potentially pathogenic gastro-intestinal microorganisms. 
Improved lactose digestion  
The claimed effect, which is proposed for further assessment, relates to improved lactose digestion. 
Improved lactose digestion is a beneficial physiological effect for individuals with lactose 
maldigestion. 
Health claims related to a combination of bacterial strains (further assessment) 
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No human intervention studies were provided from which conclusions could be drawn for the 
scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of L. acidophilus BCCM/LMG P-18806, 
L. delbrueckii BCCM/LMG P-18805 and S. thermophilus BCCM/LMG P-18807 and improved lactose 
digestion. 
Reduction in numbers of circulating CD34
+
 cells 
The claimed effect, which is proposed for further assessment, relates to a reduction in numbers of 
circulating CD34
+
 cells. The proposed target population is the general population. The Panel notes that 
reduction in numbers of circulating CD34
+
 cells is not a beneficial physiological effect per se, but 
needs to be linked to a beneficial physiological or clinical outcome.  
The Panel considers that the evidence provided did not establish that reduction in numbers of 
circulating CD34
+
 cells is a beneficial physiological effect. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of L. acidophilus BCCM/LMG P-18806, 
L. delbrueckii BCCM/LMG P-18805 and S. thermophilus BCCM/LMG P-18807 and a beneficial 
physiological effect related to reduction in numbers of circulating CD34
+
 cells. 
Health claims related to a combination of bacterial strains (further assessment) 
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health claims 
would be eligible for further assessment by EFSA in order to be able to take a final decision on 
whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect. 
Following an opinion of the NDA Panel pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 in 
which the Panel concluded that the data available were not sufficient to characterise a combination of 
Lactobacillus acidophilus P-18806 (ID 2946, 2947), Lactobacillus delbrueckii P-18805 (ID 2951, 
2952) and Streptococcus thermophilus P-18807 (ID 2974, 2975) (EFSA Panel on Dietetic Products 
Nutrition and Allergies (NDA), 2009, 2010), EFSA received additional information from the 
competent Authority of Italy for further assessment of these claims. The information provided in the 
framework of further assessment for the health claims which are the subject of this opinion is tabulated 
in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent  
The food constituent that was the subject of the health claims in the initial assessment was 
Lactobacillus acidophilus P-18806 (ID 2946, 2947), Lactobacillus delbrueckii P-18805 (ID 2951, 
2952) or Streptococcus thermophilus P-18807 (ID 2974, 2975), individually. For further assessment, 
and from the proposed wording and conditions of use, the Panel assumes that the food constituent that 
is the subject of the health claims is a combination of Lactobacillus acidophilus BCCM/LMG 
P-18806, Lactobacillus delbrueckii BCCM/LMG P-18805 and Streptococcus thermophilus 
BCCM/LMG P-18807.  
For L. acidophilus BCCM/LMG P-18806 a culture collection number from the Belgian Co-ordinated 
Collections of Microorganisms (BCCM/LMG) (P-18806) was provided. The BCCM/LMG is an 
internationally recognised culture collection which has the status of an International Depositary 
Authority under the Budapest Treaty. In the LMG, cultures can be deposited in a restricted-access 
collection for safe deposit or for patent purposes. Data on the identification and characterisation of 
L. acidophilus BCCM/LMG P-18806 at species and strain level, by using different phenotypic (cell 
morphology, carbohydrate fermentation profile, PAGE) and genotypic (16S rRNA gene sequence 
analysis, ARDRA, Rep-PCR, PFGE) methods, were provided in the applications for further 
assessment and in the accompanying references (AAT, 2011a, unpublished; BCCM/LMG, 1999, 
unpublished; Dondi, 2000). The Panel considers that L. acidophilus BCCM/LMG P-18806 is 
sufficiently characterised. 
For L. delbrueckii BCCM/LMG P-18805, a culture collection number from the BCCM/LMG, 
P-18805, was provided. Data on the identification and characterisation of L. delbrueckii BCCM/LMG 
P-18805 at species and strain level, by using different phenotypic (carbohydrate fermentation profiles, 
PAGE) and genotypic (16S rRNA gene sequence analyses, ARDRA, Rep-PCR, AFLP) methods, were 
provided in the applications for further assessment and in the accompanying references (AAT, 2011b, 
unpublished, 2011c, unpublished; BCCM/LMG, 1999, unpublished; Dondi, 2000). The Panel 
considers that L. delbrueckii BCCM/LMG P-18805 is sufficiently characterised. 
For S. thermophilus BCCM/LMG P-18807, a culture collection number from the BCCM/LMG, 
P-18807, was provided. Data on the identification and characterisation of S. thermophilus 
BCCM/LMG P-18807 at species and strain level, by using different phenotypic (carbohydrate 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
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fermentation profile, PAGE) and genotypic (16S rRNA gene sequence analysis, ARDRA, Rep-PCR, 
PFGE) methods, were provided in the applications for further assessment and in the accompanying 
references (AAT, 2011d, unpublished; BCCM/LMG, 1999, unpublished; Dondi, 2000). The Panel 
considers that S. thermophilus BCCM/LMG P-18807 is sufficiently characterised. 
The Panel considers that the food constituent, a combination of L. acidophilus BCCM/LMG P-18806, 
L. delbrueckii BCCM/LMG P-18805 and S. thermophilus BCCM/LMG P-18807, which is the subject 
of the claims, is sufficiently characterised. 
2. Relevance of the claimed effect to human health  
2.1. Reduction of gastro-intestinal discomfort (ID 2946, 2951, 2974) 
The claimed effect, which is proposed for further assessment, is: “Is a probiotic; Contributes to a 
healthy digestive system by supporting the gut flora through an increased number of positive 
lactobacillus in the intestine; useful to maintain a healthy intestinal flora by adhering to the mucosa; 
Improves intestinal barrier function by competing (steric encumbrance) against pathogens; Reduces 
gastro-intestinal discomfort; Necessary to maintain a healthy digestive system by production of 
specific enzymes (e.g.: beta-galactosidase)”. The proposed target population is the general population. 
The Panel considers that reduction of gastro-intestinal discomfort is a beneficial physiological effect. 
2.2. Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 2946, 2951, 2974) 
The claimed effect, which is proposed for further assessment, is: “Is a probiotic; Contributes to a 
healthy digestive system by supporting the gut flora through an increased number of positive 
lactobacillus in the intestine; useful to maintain a healthy intestinal flora by adhering to the mucosa; 
Improves intestinal barrier function by competing (steric encumbrance) against pathogens; Reduces 
gastro-intestinal discomfort; Necessary to maintain a healthy digestive system by production of 
specific enzymes (e.g.: beta-galactosidase)”. The proposed target population is the general population. 
The Panel notes that it is not possible to define the exact number of the different microbial groups 
which constitute a normal microbiota. Increasing the number of any groups of microorganisms, 
including lactobacilli, is not in itself considered to be a beneficial physiological effect.  
The Panel assumes that the claimed effect refers to a decrease in potentially pathogenic 
gastro-intestinal microorganisms. The Panel considers that decreasing potentially pathogenic 
gastro-intestinal microorganisms might be a beneficial physiological effect. 
2.3. Improved lactose digestion (ID 2946, 2951, 2974) 
The claimed effect, which is proposed for further assessment, is: “Is a probiotic; Contributes to a 
healthy digestive system by supporting the gut flora through an increased number of positive 
lactobacillus in the intestine; useful to maintain a healthy intestinal flora by adhering to the mucosa; 
Improves intestinal barrier function by competing (steric encumbrance) against pathogens; Reduces 
gastro-intestinal discomfort; Necessary to maintain a healthy digestive system by production of 
specific enzymes (e.g.: beta-galactosidase)”. The proposed target population is the general population. 
The Panel assumes that the claimed effect refers to improved lactose digestion and that the target 
population is individuals with lactose maldigestion. Lactose maldigestion is a common condition 
caused by reduced levels of intestinal lactase.   
The Panel considers that improved lactose digestion is a beneficial physiological effect for individuals 
with lactose maldigestion. 
Health claims related to a combination of bacterial strains (further assessment) 
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2.4. Reduction in numbers of circulating CD34+ cells (ID 2947, 2952, 2975) 
The claimed effect, which is proposed for further assessment, is: “Increases the immune 
defences/response by reducing the CD34
+
 cells; Necessary to maintain the natural defences/helps to 
maintain a balanced immune system (reducing the CD34
+
 cells)”. The proposed target population is 
the general population. 
The Panel notes that the claimed effect, “increases the immune defences/necessary to maintain the 
natural defences/maintain a balanced immune system”, is not sufficiently defined and assumes that the 
claimed effect relates to the reduction in numbers of circulating CD34
+
 cells.  
The Panel notes that reduction in numbers of circulating CD34
+
 cells is not a beneficial physiological 
effect per se, but needs to be linked to a beneficial physiological or clinical outcome. 
Most of the references provided in relation to the claim were on methodologies for bacterial strain 
identification. One open-label, non-randomised and non-controlled human study (Mastrandrea et al., 
2004) investigated the effects of a combination of L. acidophilus P-18806, L. delbrueckii P-18805 and 
S. thermophilus P-18807 on the numbers of circulating CD34
+
 human progenitor cells in 14 subjects 
with atopic disorders (clinical symptoms of asthma and/or conjunctivitis, rhinitis, urticaria, atopic 
dermatitis, food allergy) and/or irritable bowel syndrome.  
The Panel considers that the evidence provided does not establish that reduction in numbers of 
circulating CD34
+
 cells is a beneficial physiological effect. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of L. acidophilus BCCM/LMG P-18806, L. delbrueckii BCCM/LMG 
P-18805 and S. thermophilus BCCM/LMG P-18807 and a beneficial physiological effect related to 
reduction in numbers of circulating CD34
+
 cells. 
3. Scientific substantiation of the claimed effect  
3.1. Reduction of gastro-intestinal discomfort (ID 2946, 2951, 2974) 
Most of the references provided were on L. acidophilus strains other than the one which is part of the 
combination of microorganisms (Bernet et al., 1994), and on methodologies for bacterial strain 
identification (Giraffa et al., 1998; Jensen et al., 1993; Miteva et al., 2001; Moschetti et al., 1998; 
Ventura et al., 2000). A patent on methods for selection of Lactobacillus strains with ability to adhere 
to human mucosa (Dondi, 2000), by which the strains that are the subject of the claim were isolated, 
and a human intervention study on the viability of yogurt bacteria (e.g. L. delbrueckii subsp. 
bulgaricus and S. thermophilus) through the human intestinal tract (Elli et al., 2006) were also 
provided. The Panel notes that these studies did not address effects of the combination of strains that is 
the subject of the claim, notes that these studies did not address outcome measures related to the 
claimed effect, and considers that no conclusions can be drawn from these studies for the scientific 
substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of L. acidophilus BCCM/LMG P-18806, L. delbrueckii BCCM/LMG 
P-18805 and S. thermophilus BCCM/LMG P-18807 and reduction of gastro-intestinal discomfort.  
3.2. Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 2946, 2951, 2974) 
Most of the references provided were on L. acidophilus strains other than the one which is part of the 
combination of microorganisms (Bernet et al., 1994), and on methodologies for bacterial strain 
identification (Giraffa et al., 1998; Jensen et al., 1993; Miteva et al., 2001; Moschetti et al., 1998; 
Ventura et al., 2000). A patent on methods for selection of Lactobacillus strains with ability to adhere 
to human mucosa (Dondi, 2000), by which the strains that are the subject of the claim were isolated, 
Health claims related to a combination of bacterial strains (further assessment) 
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was also provided. In the patent it was only indicated how the mucosa-adhesion ability of the lactic 
acid bacterial strains and pathogens was measured. A human intervention study on the viability of 
yogurt bacteria (e.g. L. delbrueckii subsp. bulgaricus and S. thermophilus) through the human 
intestinal tract (Elli et al., 2006) was also provided. The Panel notes that these studies did not address 
effects of the combination of strains that is the subject of the claim, notes that they did not address 
outcome measures related to the claimed effect, and considers that no conclusions can be drawn from 
these studies for the scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of L. acidophilus BCCM/LMG P-18806, L. delbrueckii BCCM/LMG 
P-18805 and S. thermophilus BCCM/LMG P-18807 and decreasing potentially pathogenic gastro-
intestinal microorganisms.  
3.3. Improved lactose digestion (ID 2946, 2951, 2974) 
Most of the references provided were on L. acidophilus strains other than the one which is part of the 
combination of microorganisms (Bernet et al., 1994), and on methodologies for bacterial strain 
identification (Giraffa et al., 1998; Jensen et al., 1993; Miteva et al., 2001; Moschetti et al., 1998; 
Ventura et al., 2000). A patent on methods for selection of lactobacilli strains with ability to adhere to 
human mucosa (Dondi, 2000), by which the strains that are the subject of the claim were isolated and a 
human intervention study on the viability of yogurt bacteria (i.e. L. delbrueckii subsp. bulgaricus and 
S. thermophilus) through the human intestinal tract (Elli et al., 2006) were also provided. The Panel 
notes that these studies did not address effects of the combination of strains that is the subject of the 
claim, notes that they did not address outcome measures related to the claimed effect, and considers 
that no conclusions can be drawn from these studies for the scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of L. acidophilus BCCM/LMG P-18806, L. delbrueckii BCCM/LMG 
P-18805 and S. thermophilus BCCM/LMG P-18807 and improved lactose digestion.  
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, a combination of L. acidophilus BCCM/LMG P-18806, L. delbrueckii 
BCCM/LMG P-18805 and S. thermophilus BCCM/LMG P-18807, which is the subject of the 
health claims, is sufficiently characterised. 
Reduction of gastro-intestinal discomfort (ID 2946, 2951, 2974) 
 The claimed effect proposed for further assessment relates to a reduction of gastro-intestinal 
discomfort. The proposed target population is the general population. Reduction of 
gastro-intestinal discomfort is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of a 
combination of L. acidophilus BCCM/LMG P-18806, L. delbrueckii BCCM/LMG P-18805 
and S. thermophilus BCCM/LMG P-18807 and reduction of gastro-intestinal discomfort. 
Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 2946, 2951, 2974) 
 The claimed effect proposed for further assessment relates to a decrease in potentially 
pathogenic gastro-intestinal microorganisms. The proposed target population is the general 
population. Decreasing potentially pathogenic gastro-intestinal microorganisms might be a 
beneficial physiological effect. 
Health claims related to a combination of bacterial strains (further assessment) 
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 A cause and effect relationship has not been established between the consumption of a 
combination of L. acidophilus BCCM/LMG P-18806, L. delbrueckii BCCM/LMG P-18805 
and S. thermophilus BCCM/LMG P-18807 and decreasing potentially pathogenic gastro-
intestinal microorganisms. 
Improved lactose digestion (ID 2946, 2951, 2974) 
 The claimed effect proposed for further assessment relates to improved lactose digestion. 
Improved lactose digestion is a beneficial physiological effect for individuals with lactose 
maldigestion. 
 A cause and effect relationship has not been established between the consumption of a 
combination of L. acidophilus BCCM/LMG P-18806, L. delbrueckii BCCM/LMG P-18805 
and S. thermophilus BCCM/LMG P-18807 and improved lactose digestion. 
Reduction in numbers of circulating CD34
+
 cells (ID 2947, 2952, 2975) 
 The claimed effect proposed for further assessment relates to a reduction in numbers of 
circulating CD34
+
 cells. The proposed target population is the general population. The 
evidence provided did not establish that reduction in numbers of circulating CD34
+
 cells is a 
beneficial physiological effect.  
 A cause and effect relationship has not been established between the consumption of a 
combination of L. acidophilus BCCM/LMG P-18806, L. delbrueckii BCCM/LMG P-18805 
and S. thermophilus BCCM/LMG P-18807 and a beneficial physiological effect related to 
reduction in numbers of circulating CD34
+
 cells. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment 
(No: EFSA-Q-2012-00180, EFSA-Q-2012-00181, EFSA-Q-2012-00184, EFSA-Q-2012-00185, 
EFSA-Q-2012-00202, EFSA-Q-2012-00203). The scientific substantiation is based on the information 
provided by the competent Authority of Italy for further assessment of this claim (available on: 
http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
REFERENCES  
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taxonomic identity of the bacterial strain, Lactobacillus acidophilus P-18806, using molecular 
methods. 
AAT (Advanced Analytical Technologies), 2011b, unpublished. Report on confirmation of the 
taxonomic identity of the bacterial strain, Lactobacillus delbrueckii P-18805, using molecular 
methods. 
AAT (Advanced Analytical Technologies), 2011c, unpublished. Report on sample key for AFLP 
study. 
AAT (Advanced Analytical Technologies), 2011d, unpublished. Report on confirmation of the 
taxonomic identity of the bacterial strain, Streptococcus thermophilus I-18807, using molecular 
methods. 
BCCM/LMG (Belgian Coordinated Collections of Microorganisms/Laboratorium voor Microbiologie 
Universiteit Gent), 1999, unpublished. Report on the determination of carbohydrate fermentation 
pattern SDS-PAGE protein profiling. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
5
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
6
  
Foods are commonly involved in many different functions
7
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to a 
single food is scientifically pertinent.  
It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
                                                     
5  OJ L12, 18/01/2007 
6  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
7  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific data, 
and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the 
application for authorisation of health claims consistent criteria for the potential sources of scientific 
data. Such sources may not be available for all health claims. Nevertheless it will be relevant and 
important that EFSA comments on the availability and quality of such data in order to allow the 
regulator to judge and make a risk management decision about the acceptability of health claims 
included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not enough 
to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, 
the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified 
functions in the body in a way which is relevant to health. Although an appreciation of the beneficial 
effect in relation to the nutritional status of the European population may be of interest, the presence or 
absence of the actual need for a nutrient or other substance with nutritional or physiological effect for 
that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic or 
cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the 
body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which specifies 
this by using the word "flexibility". 
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The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be 
specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings should 
be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" 
should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or 
"helps".  
In addition, for functions affected by a large number of dietary factors it should be considered whether 
wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the 
scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally accepted 
scientific evidence by taking into account the totality of the available scientific data, and by 
weighing the evidence. In this context EFSA is invited to comment on the nature and quality 
of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent 
to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
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 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Health claims related to various microorganisms, a combination of L. acidophilus BCCM/LMG P-18806, L. delbrueckii BCCM/LMG P-18805 and 
S. thermophilus BCCM/LMG P-18807, including conditions of use, as proposed in the framework of further assessment. 
ID Food or Food constituent Health Relationship Proposed wording 
2946 Lactobacillus acidophilus 
BCCM/LMG P-18806 
Is a probiotic;  
Contributes to a healthy digestive system by supporting the gut flora through an 
increased number of positive lactobacillus in the intestine;  
useful to maintain a healthy intestinal flora by adhering to the mucosa;  
Improves intestinal barrier function by competing (steric encumbrance) against 
pathogens;  
Reduces gastro-intestinal discomfort;  
Necessary to maintain a healthy digestive system by production of specific 
enzymes (eg: betagalactosidase). 
The probiotic mixture (constituted by 
L. acidophilus P-18806, L. delbrueckii 
P-18805 and St. thermophilus P-18807) 
maintains the balance of healthy 
intestinal microflora and regulates 
intestinal functionality by replacing 
normal, natural microflora (especially 
after antibiotic/antimycotic treatment) 
which contributes to reducing gastro-
intestinal discomfort which, for 
example, could be due to problems in 
lactose digestion. 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 1x10
7
 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
(The L. acidophilus P-18806, exerts its action in mixture with L. delbrueckii P-18805 and St. thermophilus P-18807 so the same claim is proposed for all these 
three strains.) 
ID Food or Food constituent Health Relationship Proposed wording 
2947 Lactobacillus acidophilus 
BCCM/LMG P-18806 
Increases the immune defences/response by reducing the CD34+ cells.  
As recommended by PASSCLAIM, the functional capacity of the immune system 
has been assessed by:  
The probiotic mixture (constituted by L. 
acidophilus P18806, L. delbrueckii P-
18805 and St. thermophilus P-18807) 
helps to support body’s natural 
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- measuring specific cell function in vivo e.g. production of cytokines or responce 
to antigens  
-determining the incidence and severity of infection;  
Necessary to maintain the natural defences/helps to maintain a balanced immune 
system (reducing the CD34+ cells). 
defences or helps to support the 
development of the immune system. 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 1x107 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label. 
Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The intake of this supplement is not meant as a substitute to a 
balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
(The L. acidophilus P-18806, exerts its action in mixture with L. delbrueckii P-18805 and St. thermophilus P-18807 so the same claim is proposed for all these 
three strains.) 
ID Food or Food constituent Health Relationship Proposed wording 
2951 Lactobacillus delbrueckii 
BCCM/LMG P-18805 
Is a probiotic;  
Contributes to a healthy digestive system by supporting the gut flora through an 
increased number of positive lactobacillus in the intestine;  
useful to maintain a healthy intestinal flora by adhering to the mucosa;  
Improves intestinal barrier function by competing (steric encumbrance) against 
pathogens;  
Reduces gastro-intestinal discomfort;  
Necessary to maintain a healthy digestive system by production of specific 
enzymes (eg: betagalactosidase). 
The probiotic mixture (constituted by 
L. acidophilus P-18806, L. delbrueckii 
P-18805 and St. thermophilus P-18807) 
maintains the balance of healthy 
intestinal microflora and regulates 
intestinal functionality by replacing 
normal, natural microflora (especially 
after antibiotic/antimycotic treatment) 
which contributes to reducing gastro-
intestinal discomfort which, for 
example, could be due to problems in 
lactose digestion. 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 5x10
6
 ufc per day. 
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Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: 
Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The intake of this supplement is not meant as a substitute to a 
balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
(The L. delbrueckii P-18805, exerts its action in mixture with L. acidophilus P-18806 and St.thermophilus P-18807 so the same claim is proposed for all these 
three strains.) 
ID Food or Food constituent Health Relationship Proposed wording 
2952 Lactobacillus delbrueckii 
BCCM/LMG P-18805 
Increases the immune defences/response by reducing the CD34+ cells. As 
recommended by PASSCLAIM, the functional capacity of the immune system has 
been assessed by: - 
measuring specific cell function in vivo e.g. production of cytokines or responce to 
antigens - 
determining the incidence and severity of infection; Necessary to mantain the 
natural 
defences/helps to mantain a balanced immune system (reducing the CD34+ cells). 
The probiotic mixture (constituted by 
L. acidophilus P18806, L. delbrueckii 
P-18805 and St. thermophilus P-18807) 
helps to support body’s natural 
defences or helps to support the 
development of the immune system. 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 5x106 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
(The L. delbrueckii P-18805, exerts its action in mixture with L. acidophilus P-18806 and St. thermophilus P-18807 so the same claim is proposed for all these 
three strains.) 
ID Food or Food constituent Health Relationship Proposed wording 
2974 Streptococcus thermophilus 
BCCM/LMG P18807 
Is a probiotic;  
Contributes to a healthy digestive system by supporting the gut flora through an 
increased number of positive lactobacillus in the intestine; useful to maintain a 
The probiotic mixture (constituted by L. 
acidophilus P-18806, L. delbrueckii P-
18805 and St. thermophilus P-18807) 
maintains the balance of healthy 
Health claims related to a combination of bacterial strains (further assessment) 
 
21 EFSA Journal 2012;10(8):2855 
healthy intestinal flora by adhering to the mucosa;  
Improves intestinal barrier function by competing steric encumbrance) against 
pathogens;  
Reduces gastro-intestinal discomfort;  
Necessary to maintain a healthy digestive system by production of specific 
enzymes (eg: betagalactosidase). 
intestinal microflora and regulates 
intestinal functionality by replacing 
normal, natural microflora (especially 
after antibiotic/antimycotic treatment) 
which contributes to reducing gastro-
intestinal discomfort which, for 
example, could be due to problems in 
lactose digestion. 
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 10
9
 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
preferably, on an empty stomach. 
(The St. thermophilus P-18807, exerts its action in mixture with L.acidophilus P-18806 and L.delbrueckii P-18805 so the same claim is proposed for all these 
three strains.) 
ID Food or Food constituent Health Relationship Proposed wording 
2975 Streptococcus thermophilus 
BCCM/LMG P18807 
Increases the immune defences/response by reducing the CD34+ cells. As 
recommended by PASSCLAIM, the functional capacity of the immune system has 
been assessed by: -measuring specific cell function in vivo e.g. production of 
cytokines or response to antigens -determining the incidence and severity of 
infection; Necessary to maintain the natural defences/helps to maintain a balanced 
immune system (reducing the CD34+ cells). 
The probiotic mixture (constituted by L. 
acidophilus P18806, L. delbrueckii P-
18805 and St. thermophilus P-18807) 
helps to support body’s natural 
defences or helps to support the 
development of the immune system.  
Conditions of use 
Being 'Generally Recognized as Safe' (GRAS) by the Food and Drug Administration, this health claim is destined for the general population. 
The advised condition of use of this constituent is of at least 4 x 109 ufc per day. 
Since this product's release on the market, there have not been any reported cases of undesirable side effects due to this nutrient, however, italian national law 
imposes the use of these precautions on the product label: Do not exceed the indicated dosage; Keep out of reach of children under three years of age; The 
intake of this supplement is not meant as a substitute to a balanced diet and healthy lifestyle. 
This product is presented in a soluble powder form. Dissolve the content of one sachet in water or warm milk, and drink immediately. Should be consumed, 
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preferably, on an empty stomach. 
(The St.thermophilus P-18807, exerts its action in mixture with L. acidophilus P-18806 and L. delbrueckii P-18805 so the same claim is proposed for all these 
three strains) 
 
 
 
 
Health claims related to a combination of bacterial strains (further assessment) 
 
23 EFSA Journal 2012;10(8):2855 
GLOSSARY AND ABBREVIATIONS 
AFLP   Amplified fragment length polymorphism 
ARDRA  Amplified rDNA restriction analysis 
BCCM/LMG Belgian Co-ordinated Collections of Microorganisms/Laboratorium voor 
Microbiologie, Universiteit Gent 
DNA   Deoxyribonucleic acid  
PAGE   Polyacrylamide gel electrophoresis 
PCR   Polymerase chain reaction 
PFGE   Pulsed field gel electrophoresis 
Rep-PCR  Repetitive extragenomic palindromic – PCR 
RNA   Ribonucleic acid  
